Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $1.6 in the prior trading day, SELLAS Life Sciences Group Inc (NASDAQ: SLS) closed at $1.58, down -1.25%. In other words, the price has decreased by -$1.25 from its previous closing price. On the day, 1.89 million shares were traded. SLS stock price reached its highest trading level at $1.67 during the session, while it also had its lowest trading level at $1.57.
Ratios:
Our goal is to gain a better understanding of SLS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.64 and its Current Ratio is at 4.64. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 21, 2021, initiated with a Overweight rating and assigned the stock a target price of $18.
On April 02, 2018, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $11.H.C. Wainwright initiated its Buy rating on April 02, 2018, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 12 ’25 when VAN NOSTRAND ROBERT L bought 10,000 shares for $1.48 per share. The transaction valued at 14,800 led to the insider holds 20,400 shares of the business.
Wasman Jane bought 20,000 shares of SLS for $33,800 on May 30 ’25. The Director now owns 30,400 shares after completing the transaction at $1.69 per share. On May 22 ’25, another insider, Kalin Katherine Bach, who serves as the Director of the company, bought 20,000 shares for $1.80 each. As a result, the insider paid 36,000 and bolstered with 41,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLS now has a Market Capitalization of 157648464 and an Enterprise Value of 130121432.
Stock Price History:
The Beta on a monthly basis for SLS is 2.53, which has changed by 0.33898306 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, SLS has reached a high of $2.27, while it has fallen to a 52-week low of $0.77. The 50-Day Moving Average of the stock is -10.67%, while the 200-Day Moving Average is calculated to be 15.57%.
Shares Statistics:
The stock has traded on average 2.93M shares per day over the past 3-months and 1616060 shares per day over the last 10 days, according to various share statistics. A total of 99.78M shares are outstanding, with a floating share count of 97.67M. Insiders hold about 2.11% of the company’s shares, while institutions hold 20.54% stake in the company. Shares short for SLS as of 1752537600 were 27735843 with a Short Ratio of 9.47, compared to 1749772800 on 18897977. Therefore, it implies a Short% of Shares Outstanding of 27735843 and a Short% of Float of 28.09.
Earnings Estimates
SELLAS Life Sciences Group Inc (SLS) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.06 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.25 and -$0.42 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.38, with 3.0 analysts recommending between -$0.3 and -$0.45.
